![Stanford School of Medicine's 2nd Annual Conference on Disability in Healthcare and Medicine](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2020/10/Screen-Shot-2021-03-04-at-10.39.22-AM-e1614883544333-300x300.jpeg)
Date: April 10, 2021 (8 AM-6PM)
-
- 8 AM-8:20 AM opening remarks Zainub and Pete
- 8:20 AM-9:20 AM Talk 1 “I fought the law and no one won”
- 10 minute Break
- 9:30 AM-10:30 AM talk 2 students and doctors with disabilities panel
- 20 minute break
-
- 10:50 AM-11:50 AM Breakout
- One hour lunch (TBD)
- 12:50 PM-1:50 PM Talk 3 the frontiers of disability research
- Lisa Meeks is moderating
- Bonnie Swenor invited
- 10 minute break
- 2:00 PM-3:00 PM breakout 2
- 10 minute break
- 3:10 PM-4:10 PM talk 4 do-it-yourself disability advocacy (Poullos/Tolchin with students)
- 4:10 PM-4:30 PM closing remarks
- 4:30 PM-6 PM virtual happy hour
![Radiology-Wide Research Meeting](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2021/03/research-meeting-300x133.png)
Radiology Department-Wide Research Meeting
• Research Announcements
• Michelle James, PhD – Detecting and Tracking Immune Responses in the Brain and Beyond using PET
• Ryan Spitler, PhD – Precision Health and Integrated Diagnostics (PHIND) Center
Location: Zoom – Details can be found here: https://radresearch.stanford.edu
Meetings will be the 3rd Friday of each month.
Hosted by: Brian Hargreaves, PhD
Sponsored by: the the Department of Radiology
![PHIND Seminar - Manuel Garcia-Toca, M.D. & Oliver O. Aalami, M.D. @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/2020.4_SpeakerMashUp_V2-01-300x150.png)
PHIND Seminar Series: Impact of the Veterans Affairs National Abdominal Aortic Screening Program
Manuel Garcia-Toca, M.D.
Clinical Professor of Surgery
Chief, Division of Vascular Surgery
Santa Clara Valley Medical Center (SCVMC)
Oliver O. Aalami, M.D.
Clinical Associate Professor of Surgery, Vascular Surgery
Lucile Packard Children’s Hospital
Location: Zoom
Webinar URL: https://stanford.zoom.us/s/98417624095
Dial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
Webinar ID: 984 1762 4095
Passcode: 111283
11:00am – 12:00pm Seminar & Discussion
RSVP Here
ABSTRACT
Background: The U.S. Federal Government enacted the Screen for Abdominal Aortic Aneurysms Very Efficiently Act in January 2007. Simultaneously, the Department of Veterans Affairs (VA) implemented a more inclusive AAA screening policy for veteran beneficiaries shortly afterwards.
Our study aimed to evaluate the impact of the VA program on AAA detection rate and all-cause mortality compared to a cohort of patients whose aneurysms were identified by other abdominal imaging.
Methods: We identified veterans with an AAA screening study using the two existing Current Procedural Terminology (CPT) codes (G0389 and 76706). In the comparison group, eligible abdominal imaging studies included ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) queried according to CPT codes between 2001 and 2018.
We used a difference-in-differences regression model to evaluate the change in aneurysm detection rate and all-cause mortality five years before and eleven years after the VA implemented the screening policy in 2007.
We calculated survival estimates after AAA screening or non-screening imaging of patients with or without AAA diagnosis and used multivariate Cox regression model to evaluate mortality in patients with a positive AAA diagnosis adjusting for patient characteristics and comorbidities.
Results: We identified 3.9 million veterans with abdominal imaging, a total of 303,664 of whom were coded has having an AAA US screening between 2007 and 2018. An AAA diagnosis was made in 4.84% of the screening group vs. 1.3% in the non-screening imaging group P<0.001, yet more aneurysms were found with general imaging studies (50,730 vs.15,449) (Fig 1).
On Kaplan-Meier survival analysis, patients with an AAA diagnosis had higher overall mortality than patients who screened normal; patients with aneurysms found with non-screening imaging had the highest mortality, log-rank P<0.001 (Fig 2).
The difference in differences regression analysis, showed that the absolute AAA detection rate was 1.55% higher (95% CI 1.2- 1.8), and the mortality was 13.89 % lower (95% CI 10.18 %-16.66 %) after the introduction of the screening program in 2007.
Multivariate Cox regression analysis in patients with AAA diagnosis (65-74-year-old) demonstrated a significantly lower 5-year mortality [HR 0.45 (95% CI 0.43-0.48)] for patients in the US Screening group P<0.001.
Conclusions: In a nationwide analysis of VA patients, implementation of AAA screening was associated with improved survival and a higher rate of AAA diagnosis. These findings provide further support for this program’s continuation versus defaulting to incidental recognition following other abdominal imaging.
ABOUT MANUEL GARCIA-TOCA
Dr. Garcia-Toca earned his medical degree at the Universidad Anahuac in Mexico 1999. He has a master’s degree in Health Policy from Stanford University.
He received his general surgery training at the Massachusetts General Hospital and Brown University in 2008. He then completed a Vascular Surgery fellowship at Northwestern University in 2010. Dr. Garcia-Toca is board certified in both surgery and vascular surgery.
Dr. Garcia-Toca joined Stanford Vascular Surgery in 2015. He is currently Clinical Professor of Surgery in the Division of Vascular Surgery. Dr. Garcia-Toca had previously served as an Assistant Professor of Surgery at Brown University. Dr. Garcia Toca is a Staff Surgeon at Santa Clara Valley Medical Center in San Jose.
His research interests include new therapeutic strategies and outcomes for the management of vascular trauma, cerebrovascular diseases, dialysis access, aortic dissection and aneurysms.
ABOUT OLIVER O. AALAMI
Dr. Aalami is a Clinical Associate Professor of Vascular & Endovascular Surgery at Stanford University and the Palo Alto VA and serves as the Lead Director of Stanford’s Biodesign for Digital Health. He is the course director for Biodesign for Digital Health, Building for Digital Health and co-founder of the open source project, CardinalKit, developed to support sensor-based mobile research projects. His primary research focuses on clinically validating the sensors in smartphones and smartwatches in patients with cardiovascular disease to further precision health implementation.
Hosted by: Garry Gold, M.D.
Sponsored by the PHIND Center and the Department of Radiology
Imon Banerjee, PhD
Assistant Professor
Co-director Medical and Health Informatics Core (MHIC)
Department of Biomedical Informatics
Department of Radiology
Member of Winship Cancer Institute
Emory School of Medicine
Fusion of Multi-Modal Data Stream for Clinical Event Prediction – Simulating Physicians’ Workflow
Abstract:
Advancements in machine learning and deep learning techniques carry the potential to make significant contributions to healthcare, particularly in fields of diagnosis, prognosis, and treatment decisions. However, most of current state-of-the-art machine learning and deep learning models for healthcare applications consider only a single input data stream without data informing clinical context. The trend of ignoring clinical contextual information is particularly prominent when dealing with the diagnosis and prognosis tasks where the imaging data is accessible. Yet in practice, pertinent and accurate non-imaging data based on the clinical history and laboratory data enable physicians to interpret imaging findings in the appropriate clinical context, leading to a higher diagnostic accuracy, informative clinical decision making, and improved patient outcomes. To achieve a similar goal using machine learning and increase the physician trust, clinical diagnosis and prognosis models must also achieve the capability to process contextual clinical data from electronic health records (EHR) in addition to pixel or other sensor data. This talk will present multiple fusion machine learning models on the imaging data with boosted performance by integrating the clinical context. In addition to imaging, I will also present a smart flexible sensor patch with on-chip AI capability that can be used in homecare to generate advance alert of cardiovascular abnormality by combining physiological signal data with patient demographic and comorbidity information.
![MIPS Seminar - Jennifer Dionne, PhD @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/jennifer-dionne_profilephoto-300x300.jpg)
MIPS Seminar Series: Emerging nanophotonic platforms for infectious disease diagnostics: Re-imagining the conventional microbiology toolkit
Jennifer Dionne, PhD
Senior Associate Vice Provost for Research Platforms/Shared Facilities
Associate Professor of Material Science and Engineering and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Stanford University
Location: Zoom
Webinar URL: https://stanford.zoom.us/j/95883654314
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 958 8365 4314
Passcode: 105586
12:00pm – 12:45pm Seminar & Discussion
RSVP Here
ABSTRACT
We present our research controlling light at the nanoscale for infectious disease diagnostics, including detecting bacteria at low concentration, sensing COVID gene sequences, and visualizing in-vivo inter-cellular forces. First, we combine Raman spectroscopy and deep learning to accurately classify bacteria by both species and antibiotic resistance in a single step. We design a convolutional neural network (CNN) for spectral data and train it to identify 30 of the most common bacterial strains from single-cell Raman spectra, achieving antibiotic treatment identification accuracies exceeding 99% and species identification accuracies similar to leading mass spectrometry identification techniques. Our combined Raman-CNN system represents a proof-of-concept for rapid, culture-free identification of bacterial isolates and antibiotic resistance. Second, we describe resonant nanophotonic surfaces, known as “metasurfaces” that enable multiplexed detection of SARS-CoV-2 gene sequences. Our metasurfaces utilize guided mode resonances excited in high refractive index nanostructures. The high quality factor modes produce a large amplification of the electromagnetic field near the nanostructures that increase the response to targeted binding of nucleic acids; simultaneously, the optical signal is beam-steered for multiplexed detection. We describe how this platform can be manufactured at scale for portable, low-cost assays. Finally, we introduce a new class of in vivo optical probes to monitor biological forces with high spatial resolution. Our design is based on upconverting nanoparticles that, when excited in the near-infrared, emit light of a different color and intensity in response to nano-to-microNewton forces. The nanoparticles are sub-30nm in size, do not bleach or photoblink, and can enable deep tissue imaging with minimal tissue autofluorescence. We present the design, synthesis, and characterization of these nanoparticles both in vitro and in vivo, focusing on the forces generated by the roundworm C. elegans as it feeds and digests its bacterial food.
ABOUT
Jennifer Dionne is the Senior Associate Vice Provost of Research Platforms/Shared Facilities and an associate professor of Materials Science and Engineering and, by courtesy, of Radiology at Stanford. She is also an Associate Editor of Nano Letters, director of the DOE-funded Photonics at Thermodynamic Limits Energy Frontier Research Center, and an affiliate faculty of the Wu Tsai Neurosciences Institute, the Institute for Immunity, Transplantation, and Infection, and Bio-X. Jen received her B.S. degrees in Physics and Systems Science and Mathematics from Washington University in St. Louis, her Ph. D. in Applied Physics at the California Institute of Technology in 2009, and her postdoctoral training in Chemistry at Berkeley. Her research develops nanophotonic methods to observe and control chemical and biological processes as they unfold with nanometer scale resolution, emphasizing critical challenges in global health and sustainability. Her work has been recognized with the Alan T. Waterman Award, a NIH Director’s New Innovator Award, a Moore Inventor Fellowship, the Materials Research Society Young Investigator Award, and the Presidential Early Career Award for Scientists and Engineers, and was featured on Oprah’s list of “50 Things that will make you say ‘Wow’!”. Beyond the lab, Jen enjoys exploring the intersection of art and science, long-distance cycling, and reliving her childhood with her two young sons.
Hosted by: Katherine Ferrara, PhD
Sponsored by: Molecular Imaging Program at Stanford & the Department of Radiology
![Racial Equity Challenge: Race in society @ Zoom](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2021/04/shield.png)
Targeted violence continues against Black Americans, Asian Americans, and all people of color. The department of radiology diversity committee is running a racial equity challenge to raise awareness of systemic racism, implicit bias and related issues. Participants will be provided a list of resources on these topics such as articles, podcasts, videos, etc., from which they can choose, with the “challenge” of engaging with one to three media sources prior to our session (some videos are as short as a few minutes). Participants will meet in small-group breakout sessions to discuss what they’ve learned and share ideas.
Please reach out to Marta Flory, flory@stanford.edu with questions. For details about the session, including recommended resources and the Zoom link, please reach out to Meke Faaoso at mfaaoso@stanford.edu.
![Cancer Early Detection Seminar Series - Michael Berger, Ph.D. @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/berger_160204_07-2_3x2-300x200.jpg)
CEDSS: “Building a Scalable Clinical Genomics Program: How tumor, normal, and plasma DNA sequencing are informing cancer care, cancer risk, and cancer detection”
Elizabeth and Felix Rohatyn Chair & Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Memorial Sloan Kettering Cancer Center
Zoom Details
Meeting URL: https://stanford.zoom.us/s/92559505314
Dial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
Meeting ID: 925 5950 5314
Passcode: 418727
11:00am – 12:00pm Seminar & Discussion
RSVP Here
ABSTRACT
Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of oncogenomic mutations that can be targeted therapeutically. To accelerate enrollment to clinical trials of molecularly targeted agents and guide treatment selection, we have established a center-wide, prospective clinical sequencing program at Memorial Sloan Kettering Cancer Center using a custom, paired tumor-blood normal sequencing assay (MSK-IMPACT), which we have used to profile more than 50,000 patients with solid tumors. Yet beyond just the characterization of tumor-specific alterations, the inclusion of blood DNA has readily enabled the identification of germline risk alleles and somatic mutations associated with clonal hematopoiesis. To complement this approach, we have also implemented a ‘liquid biopsy’ cfDNA panel (MSK-ACCESS) for cancer detection, surveillance, and treatment selection and monitoring. In my talk, I will describe the prevalence of somatic and germline genomic alterations in a real-world population, the clinical benefits of cfDNA assessment, and how clonal hematopoiesis can inform cancer risk and confound liquid biopsy approaches to cancer detection.
ABOUT
Michael Berger, PhD, holds the Elizabeth and Felix Rohatyn Chair and is Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center, a multidisciplinary initiative to promote precision oncology through genomic analysis to guide the diagnosis and treatment of cancer patients. He is also an Associate Attending Geneticist in the Department of Pathology with expertise in cancer genomics, computational biology, and high-throughput DNA sequencing technology. His laboratory is developing experimental and computational methods to characterize the genetic makeup of individual cancers and identify genomic biomarkers of drug response and resistance. As Scientific Director of Clinical NGS in the Molecular Diagnostics Service, he oversees the development and bioinformatics associated with clinical sequencing assays, and he helped lead the development and implementation of MSK-IMPACT, a comprehensive FDA-authorized tumor sequencing panel that been used to profile more than 60,000 tumors from advanced cancer patients at MSK. The resulting data have enabled the characterization of somatic and germline biomarkers across many cancer types and the identification of mutations associated with clonal hematopoiesis. Dr. Berger also led the development of a clinically validated plasma cell-free DNA assay, MSK-ACCESS, which his laboratory is using to explore tumor evolution, acquired drug resistance, and occult metastatic disease. He received his Bachelor’s Degree in Physics from Princeton University and his Ph.D. in Biophysics from Harvard University.
Hosted by: Utkan Demirci, Ph.D.
Sponsored by: The Canary Center & the Department of Radiology
Stanford University – School of Medicine
![MIPS Special Seminar - Jubilant Biosys @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/Headshots-for-Calendar.jpg)
MIPS Special Seminar: Jubilant Biosys: Drug discovery and contract research services, from target discovery to candidate selection
Thomas Haywood, PhD
Head of International Radiochemistry Collaborations
Stanford University
Saurabh Kapure, MBA
Vice President, Business Development (USA & APAC)
Jubilant Biosys Limited
Jay Sheth, MBA
Manager Business Development, Drug Discovery Services, and CDMO
Jubilant Biosys Limited
LOCATION: Zoom
Meeting URL: https://stanford.zoom.us/j/98108346345
Dial: +1 650 724 9799 or +1 833 302 1536
Meeting ID: 981 0834 6345
Passcode: 397741
9:00-9:15 AM, PT – Thomas Haywood – Stanford Radiology projects
9:40-10:00 AM, PT – Moderated by Jason Thanh Lee – Discussion
ABOUT
Jubilant Biosys, an integrated contract research organization in India with business offices in Asia and North America, is a leading collaborator for biotechnology and pharmaceutical companies, with in-depth expertise in discovery informatics, medicinal chemistry, structural biology, and in vitro pharmacology services. Jubilant Biosys provides comprehensive drug discovery services and contract research services, from target discovery to candidate selection and with flexible business models (FFS, FTE and risk shared). This seminar will showcase case studies from recent Stanford projects and a discussion of future opportunities.
Sponsored by: Molecular Imaging Program at Stanford, Department of Radiology
![PHIND Seminar - Patricia A. Deverka, MD, MS, MBE & Kathryn A. Phillips, PhD @ Zoom - See Description for Zoom Link](https://web.stanford.edu/group/radweb/cgi-bin/radcalendar/wp-content/uploads/2019/10/2020.5_SpeakerMashUp.jpg)
PHIND Seminar Series: Multi-Cancer Early Detection Screening Tests – “Liquid Biopsy Tests” – Are Here – But Will Payers Provide Insurance Coverage?
Patricia A. Deverka, MD, MS, MBE
Executive Director
Deverka Consulting, LLC
Kathryn A. Phillips, PhD
Professor of Health Economics and Health Services Research
Founding Director, UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS)
Location: Zoom
Webinar URL: https://stanford.zoom.us/s/99194110894
Dial: US: +1 650 724 9799 or +1 833 302 1536 (Toll Free)
Webinar ID: 991 9411 0894
Passcode: 044958
11:00am – 12:00pm Seminar & Discussion
RSVP Here
ABSTRACT
The emergence of Multi-Cancer Early Detection Screening Tests (MCED) – “liquid biopsy screening tests” – has generated enormous interest because they could fundamentally shift how cancer screening is done. One company is already offering an MCED test for clinical use as a “lab developed test” (LDT) – and thus addressing the question of “who will pay” has become urgent. These tests offer potentially transformative screening and clinical benefits, but their characteristics present unique challenges to payer coverage decision-making and generate concerns about the potentially high cost of widespread adoption.
We will present our ongoing work on examining the unique challenges that MCED present for payer coverage decision-making, drawing on our extensive experience with coverage and reimbursement for new technologies. We will focus on identifying the evidence generation strategies that could be pursued now to inform payer decision-making so that coverage policies can be developed that are appropriate and equitable for this ground-breaking technology.
ABOUT PATRICIA A. DEVERKA
Dr. Deverka is the Executive Director at Deverka Consulting, LLC where she focuses on helping biotechnology companies and start-ups develop evidence to support payer coverage and clinical adoption of innovative technologies. Her most recent projects have focused on breakthrough tests and drugs focused on population genomic screening, cancer, and ultra-rare disorders. Prior to starting her consulting practice, Dr. Deverka has worked in the fields of health economics and outcomes research in both non-profit and for-profit settings as a researcher, educator, and department head. She has extensive experience with patient-centered outcomes research, drug and diagnostic reimbursement planning, cost- effectiveness analysis, and bioethical issues surrounding the use of new technologies. While working in academia and several non-profit firms, she has participated in numerous NIH-funded studies to evaluate policy barriers to clinical integration of new genomic technologies and has published extensively on strategies to promote evidence generation and data sharing. She is a member of the National Human Genome Research Institute (NHGRI)’s Genomic Medicine Work Group and serves as a member of NHGRI’s Advisory Council. Deverka has a medical degree from the University of Pittsburgh and is board certified in General Preventive Medicine and Public Health. She also has a master’s degree in bioethics from the University of Pennsylvania and completed a policy fellowship at Duke University’s Institute for Genome Sciences and Policy.
ABOUT KATHRYN A. PHILLIPS
Kathryn A. Phillips founded and leads the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), which focuses on developing objective evidence on how to effectively, efficiently, and equitably implement precision/personalized medicine into health care. Kathryn has published over 150 peer-reviewed articles in major journals including JAMA, New England Journal of Medicine, Science, and Health Affairs. She has had continuous funding from NIH as a PI for over 25 years and was recently awarded a 5-year NIH grant to examine payer coverage and economic value for emerging genomic technologies (cell-free DNA tests and tests based on polygenic risk scores). Kathryn serves on the editorial boards for Health Affairs, Value in Health, JAMA Internal Medicine, Genetics in Medicine; is a member of the National Academy of Medicine Roundtable on Genomics and Precision Health; and has served on the governing Board of Directors for GenomeCanada and as an advisor to the FDA, CDC, and the President’s Council of Advisors on Science and Technology. She has also served as an advisor to many diagnostics, sequencing, and pharmaceutical companies. Kathryn is Chair of the Global Economics and Evaluation of Clinical Sequencing Working Group, and a member of an evidence review committee for the Institute for Clinical and Economic Review (ICER).
Hosted by: Garry Gold, M.D.
Sponsored by the PHIND Center and the Department of Radiology
Ivana Isgum, PhD
University Professor AI & Medical Imaging
Amsterdam University Medical Centers
Department of Biomedical Engineering & Physics and
Department of Radiology & Nuclear Medicine
Amsterdam University Medical Center
Abstract:
Over the past decades, diagnostic imaging has become an integral part of modern medicine. Current increase in the number and volume of the acquired medical images has led to a tremendous increase in the expert workload for image interpretation. In recent years, deep learning has revolutionized many fields including medical imaging. It has shown potential to automate the routine analysis thereby alleviating expert workload, as well as to support clinical research. In this presentation, I will show our recent work on the development of AI-based methods to improve image quality, I will present methods we developed for quantitative analysis of CT and MRI exams, and illustrate their application in large-scale studies.